Inhibrx Biosciences, Inc. (INBX) News
Follow Inhibrx Biosciences, Inc. (INBX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Inhibrx Biosciences posts updated corporate presentation highlighting INBRX-106 and ozekibart clinical progress
Inhibrx Biosciences posted an updated investor presentation outlining strong INBRX-106 clinical signals and ozekibart registrational results.Key Highlights:Original SEC Filing: Inhibrx Biosciences, Inc. [ INBX ] - 8-K -
REGULATION | Sep 28, 2026, 09:18 PM UTC
L
Inhibrx shares jump after CEO and insiders add stake
Inhibrx Biosciences shares rose more than 7% on Wednesday following insider purchases, including CEO Mark Lappe adding to his stake.
EQUITY | Sep 09, 2026, 04:22 PM UTC
M
Inhibrx reports Phase 2 HNSCC data for INBRX-106 combination
Inhibrx said INBRX-106 plus pembrolizumab produced a 48.3% confirmed objective response rate and 9.6-month interim median PFS in first-line Phase 2 HNSCC, versus 26.5% and 4.9 months previously cited.
CENTRAL_BANK | Sep 08, 2026, 08:03 PM UTC
M
INBX data: INBRX-106 plus pembrolizumab shows efficacy in HNSCC
INBRX-106 plus pembrolizumab reported significant improvements in first-line HNSCC response rates, depth, and durability, especially in HPV-positive patients, with manageable safety. The study is planned to expand.
EQUITY | Sep 08, 2026, 02:23 PM UTC
M
Inbx-106 plus pembrolizumab shows robust first-line HNSCC efficacy
INBRX-106 plus pembrolizumab reported significant improvements in response rate, depth and durability in first-line HNSCC, especially in HPV-positive patients, with manageable safety. Study expansion and accelerated regu
CENTRAL_BANK | Sep 08, 2026, 01:16 PM UTC
M
Inhibrx trial data shows reduced tumors in mid-stage head and neck study
Inhibrx Biosciences said its experimental combination cancer drug reduced tumors in a mid-stage study of patients with a type of head and neck cancer. Shares were marginally up in premarket trading.
EQUITY | Sep 08, 2026, 12:17 PM UTC
M
Inhibrx Biosciences reports positive Phase 2 results for head and neck cancer therapy
Inhibrx Biosciences said its INBRX-106 in combination with pembrolizumab produced positive results in a Phase 2 study for metastatic or unresectable recurrent head and neck squamous cell carcinoma.
EQUITY | Sep 08, 2026, 11:57 AM UTC
M
Inhibrx says INBRX-106 nearly doubles response rate in Phase 2
Inhibrx Biosciences reported that INBRX-106 nearly doubled response rate and achieved interim median PFS of 9.6 months in its Phase 2 HNSCC study.
CENTRAL_BANK | Sep 08, 2026, 11:41 AM UTC
M
INBX’s INBRX-106 plus pembrolizumab shows superior HNSCC efficacy vs pembrolizumab
INBRX-106, a hexavalent OX40 agonist, showed superior efficacy to pembrolizumab alone in first-line recurrent/metastatic HNSCC, especially in HPV+ patients, with higher response rates and improved progression-free surviv
EQUITY | Sep 08, 2026, 11:34 AM UTC
M
INBX’s INBRX-106 plus pembrolizumab posts strong Phase 2 HNSCC results
Phase 2 HNSCC data show INBRX-106 plus pembrolizumab nearly doubled response rates and improved six-month progression-free survival, with especially strong results in HPV+ patients. The combination was well tolerated and
EQUITY | Sep 08, 2026, 11:33 AM UTC
M
Inhibrx INBRX-106 nears doubles response in Phase 2 HNSCC
Inhibrx reports INBRX-106 nearly doubles response rate and interim median PFS of 9.6 months in its Phase 2 HNSCC study.
CENTRAL_BANK | Sep 08, 2026, 11:30 AM UTC
L
INBX - Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study - Click For Rel
INBX - Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
EQUITY | Sep 04, 2026, 08:01 PM UTC
L
H.C. Wainwright initiates INBX at Buy, $245 target
H.C. Wainwright initiates INBX with a Buy rating and a $245.00 price target.
EQUITY | Aug 24, 2026, 11:59 AM UTC
L
INBX: Stifel reiterates Buy, PT $325 ahead of OX40 readout
Hammerstone MarketTalk reports Stifel reiterates a Buy rating on INBX and keeps a $325 price target, citing an attractive setup into an OX40 durability readout next month.
EQUITY | Aug 21, 2026, 11:08 AM UTC
L
Inhibrx GAAP EPS -2.34 misses by 0.06; interest expense rises
Inhibrx reports GAAP EPS of -2.34, missing by 0.06, while interest expense jumps to $4.5M from $1.3M amid debt rising to $175M from $100M.
EARNINGS | Aug 13, 2026, 08:14 PM UTC
L
Inhibrx reports second-quarter 2026 financial results
Inhibrx (INBX) reports its second quarter 2026 financial results, with details provided in the company release.
EARNINGS | Aug 13, 2026, 08:05 PM UTC
L
Citizens healthcare analysts hold an analyst/industry conference call
Citizens healthcare analysts hold an analyst/industry conference call
EQUITY | Jul 13, 2026, 08:56 AM UTC